New insider activity at Mirum Pharmaceuticals ( (MIRM) ) has taken place on January 27, 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Director Patrick Heron has significantly increased his stake in Mirum Pharmaceuticals by purchasing 131,425 shares of the company’s stock in a single transaction. The acquisition, valued at $8,999,984, underscores a major show of confidence from inside the company’s leadership and represents a substantial insider investment at Mirum Pharmaceuticals.
Recent Updates on MIRM stock
Over the last 24 hours, Mirum Pharmaceuticals’ shares moved higher in after-hours trading, up about 2.5% to roughly $101.73, helped by a sizable insider purchase in which director Patrick Heron bought about $9M of stock, signaling insider confidence. The company also closed its acquisition of Bluejay Therapeutics, adding a late-stage hepatitis delta virus (HDV) monoclonal antibody (brelovitug) with Breakthrough Therapy and PRIME designations plus additional cash, broadening its rare liver disease franchise and strengthening its balance sheet through concurrent private financings. Analysts have been raising their price targets primarily because of several fundamental drivers: strong preliminary quarterly results and guidance that beat expectations, which led firms like Baird to update their financial models more favorably; Mirum’s outlook for 2026 as a “busy” and pivotal year; and advancing clinical progress of volixibat in two chronic immune‑mediated cholestatic liver diseases, with the potential for an earlier-than-expected commercial launch. Together with the expanded pipeline from Bluejay and improved commercialization trends, these developments underpin the more optimistic long‑term assumptions behind the higher valuation views, even as some AI-based assessments still flag weaker current profitability and leverage as offsetting risks.
Spark’s Take on MIRM Stock
According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.
The score is held back primarily by weak underlying financial quality (negative profitability, negative ROE, and higher leverage) and limited valuation support (negative P/E, no dividend). Offsetting these are strong technical uptrend signals and constructive business momentum from the latest earnings call and corporate updates (raised guidance, first net income milestone, expanded pipeline via Bluejay), though momentum indicators also suggest the stock is currently overbought.
To see Spark’s full report on MIRM stock, click here.
More about Mirum Pharmaceuticals
YTD Price Performance: 22.70%
Average Trading Volume: 743,510
Technical Sentiment Signal: Buy
Current Market Cap: $5.01B